BeyondSpring | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.04.

EBIT: As of FY2025 Q3, the actual value is USD -1.809 M.

Continuing Operations

Research and Development (R&D) Expenses

• R&D expenses were $1.0 million for Q3 2025, compared to $0.6 million for Q3 2024, marking a $0.4 million increase primarily due to higher drug manufacturing expenses and increased Plinabulin combination therapy research.

General and Administrative (G&A) Expenses

• G&A expenses were $0.8 million for Q3 2025, compared to $1.7 million for Q3 2024, reflecting a $0.9 million decrease due to lower professional service costs and reduced salary expenses from decreased administrative headcount.

Net Loss

• Net loss from continuing operations was $1.7 million for Q3 2025, compared to $2.2 million for Q3 2024.

Cash and Cash Equivalents

• Cash and cash equivalents were $12.5 million as of September 30, 2025, compared to $2.9 million as of December 2024.

Discontinued Operations

Net Loss

• Net loss from discontinued operations was $3.2 million for Q3 2025, compared to $2.4 million for Q3 2024.

Current Assets

• Current assets of discontinued operations were $11.4 million as of September 2025, compared to $25.3 million as of December 2024.

Year to Date Financial Results

Continuing Operations

Research and Development (R&D) Expenses

• R&D expenses were $2.9 million for the nine months ended September 30, 2025, compared to $2.2 million for the same period in 2024, indicating a $0.7 million increase.

General and Administrative (G&A) Expenses

• G&A expenses were $3.4 million for the nine months ended September 30, 2025, compared to $4.9 million for the same period in 2024, showing a $1.5 million decrease.

Net Loss

• Net loss from continuing operations was $6.2 million for the nine months ended September 2025, compared to $6.9 million for the same period in 2024.

Discontinued Operations

Net Loss

• Net loss from discontinued operations was $2.2 million for the nine months ended September 2025, compared to $5.0 million for the same period in 2024.

Outlook / Guidance

BeyondSpring Inc. anticipates potential challenges in raising the necessary funds for future operations and acknowledges risks related to clinical trial outcomes, regulatory approvals, and market competition. The company remains committed to advancing its product candidates and meeting Nasdaq’s listing requirements.